Scispace (Formerly Typeset)
  1. Home
  2. Journals
  3. Gastroenterology
  4. 2000
  1. Home
  2. Journals
  3. Gastroenterology
  4. 2000
Showing papers in "Gastroenterology in 2000"
Journal Article•10.1053/GAST.2000.9370•
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial

[...]

Paolo Gionchetti, Fernando Rizzello, A. Venturi, Patrizia Brigidi, Diego Matteuzzi, Gabriele Bazzocchi, Gilberto Poggioli1, Mario Miglioli, Massimo Campieri •
University of Bologna1
01 Aug 2000-Gastroenterology
TL;DR: Oral administration of a probiotic preparation containing 5 x 10 per gram of viable lyophilized bacteria of 4 strains of lactobacilli, 3 strains of bifidobacteria, and 1 strain of Streptococcus salivarius subsp.

1,566 citations

Journal Article•10.1053/GAST.2000.20228•
Very High Risk of Cancer in Familial Peutz—Jeghers Syndrome

[...]

Francis M. Giardiello1, Jill D. Brensinger2, Anne C. Tersmette2, Steven N. Goodman2, Gloria M. Petersen2, Susan V. Booker2, Marcia Cruz-Correa2, Johan Offerhaus2 •
Johns Hopkins University School of Medicine1, Johns Hopkins University2
01 Dec 2000-Gastroenterology
TL;DR: Patients with Peutz-Jeghers syndrome are at very high relative and absolute risk for gastrointestinal and nongastrointestinal cancers.

1,456 citations

Journal Article•10.1016/S0016-5085(00)70168-5•
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer

[...]

Heikki Järvinen1, Markku Aarnio, Harri Mustonen, Katja Aktan–Collan‡, Lauri A. Aaltonen, Päivi Peltomäki, Albert de la Chapelle, Jukka-Pekka Mecklin •
Helsinki University Central Hospital1
01 May 2000-Gastroenterology
TL;DR: Colonic screening at 3-year intervals more than halves the risk of CRC, prevents CRC deaths, and decreases overall mortality by about 65% in HNPCC families.

1,336 citations

Journal Article•10.1016/S0016-5085(03)00171-9•
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

[...]

Paolo Gionchetti1, Fernando Rizzello1, Ulf Helwig1, A. Venturi1, Karen M. Lammers1, Patrizia Brigidi1, Beatrice Vitali1, Gilberto Poggioli1, Mario Miglioli1, Massimo Campieri1 •
University of Bologna1
01 Apr 2000-Gastroenterology
TL;DR: Treatment with VSL#3 is effective in the prevention of the onset of acute pouchitis and improves quality of life of patients with ileal pouch-anal anastomosis.

1,155 citations

Journal Article•10.1016/S0016-5085(00)70140-5•
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

[...]

Marla Dubinsky1, Stéphanie Lamothe1, Huiying Yang2, Stephan R. Targan2, Daniel Sinnett1, Yves Théorêt1, Ernest G. Seidman1 •
Université de Montréal1, Cedars-Sinai Medical Center2
01 Apr 2000-Gastroenterology
TL;DR: 6-MP metabolite levels and TPMT genotyping may assist clinicians in optimizing therapeutic response to 6-MP and identifying individuals at increased risk for drug-induced toxicity.

1,056 citations

Journal Article•10.1016/S0016-5085(00)70364-7•
Liver fibrosis in overweight patients.

[...]

Vlad Ratziu1, Philippe Giral, Frédéric Charlotte, Eric Bruckert, Vincent Thibault, Ioannis Theodorou, Lina Khalil, Gérard Turpin, Pierre Opolon, Thierry Poynard1 •
Centre national de la recherche scientifique1
01 Jun 2000-Gastroenterology
TL;DR: A clinicobiological score combining age, BMI, triglycerides, and ALT had 100% negative predictive value for septal fibrosis when scoring 0 or 1 (100% sensitivity for a specificity of 47%).

1,040 citations

Journal Article•10.1053/GAST.2000.9302•
Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

[...]

Nicholas J. Shaheen1, Melissa A. Crosby, Eugene M. Bozymski1, Robert S. Sandler1•
University of North Carolina at Chapel Hill1
01 Aug 2000-Gastroenterology
TL;DR: There was a strong correlation between cancer risk and the size of the study, with small studies reporting much higher risks of cancer than larger studies, and publication bias may be overestimated in the literature due to publication bias.

824 citations

Journal Article•10.1053/GAST.2000.8523•
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

[...]

J A Tibble, G Sigthorsson, S. Bridger, Magne K. Fagerhol, Ingvar Bjarnason 
01 Jul 2000-Gastroenterology
TL;DR: Fecal calprotectin predicts clinical relapse of disease activity in patients with Crohn's disease and UC, whereas small intestinal permeability is a useful predictor of relapse in Patients with small intestinal CD.

813 citations

Journal Article•10.1053/GAST.2000.16484•
The impact of irritable bowel syndrome on health-related quality of life.

[...]

Ian M. Gralnek, Ron D. Hays1, Ron D. Hays2, Amy M. Kilbourne3, Bruce D. Naliboff1, Emeran A. Mayer1 •
University of California, Los Angeles1, RAND Corporation2, University of Pittsburgh3
01 Sep 2000-Gastroenterology
TL;DR: Comparisons with previously reported HRQOL data for the general U.S. population and for patients with gastroesophageal reflux disease, diabetes mellitus, depression, and dialysis-dependent end-stage renal disease offer further insight into the impact of IBS on patient functional status and well-being.

788 citations

Journal Article•10.1053/GAST.2000.19576•
A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development.

[...]

Elie D. Al-Chaer1, Motohiro Kawasaki1, Pankaj J. Pasricha1•
University of Texas Medical Branch1
01 Nov 2000-Gastroenterology
TL;DR: In this paper, the abdominal withdrawal reflex and responses of viscerosensitive neurons were recorded during colon distention in a rat with either mechanical or chemical colonic irritation between postnatal days 8 and 21 and were tested when they became adults.

776 citations

Journal Article•10.1053/GAST.2000.16510•
NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2

[...]

John L. Wallace1, Webb McKnight1, Brian K. Reuter1, Nathalie Vergnolle1•
University of Calgary1
01 Sep 2000-Gastroenterology
TL;DR: Inhibition of both COX-1 andCOX-2 is required for NSAID-induced gastric injury in the rat, and the combination of SC-560 and celecoxib invariably caused hemorrhagic erosion formation, comparable to that seen with indomethacin.
Journal Article•10.1053/GAST.2000.18144•
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

[...]

James Markowitz, K Grancher, Nina Kohn1, Martin Lesser1, Fredric Daum •
North Shore-LIJ Health System1
01 Oct 2000-Gastroenterology
TL;DR: Addition of 6-MP to a regimen of corticosteroids significantly lessens the need for prednisone and improves maintenance of remission, and should be part of the initial treatment regimen for children with newly diagnosed moderate-to-severe CD.
Journal Article•10.1016/S0016-5085(00)70136-3•
Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus

[...]

Christian Ell, Andrea May, Liebwin Gossner, Oliver Pech, E. Günter, G. Mayer, R. Henrich, Michael Vieth, Hartmut Müller, Gerhard Seitz, Manfred Stolte 
01 Apr 2000-Gastroenterology
TL;DR: Endoscopic mucosal resection of early carcinoma in Barrett's esophagus is associated with promisingly low morbidity and mortality rates and may offer a new minimally invasive therapeutic alternative to esophagectomy, especially in low-risk situations.
Journal Article•10.1053/GAST.2000.19580•
Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

[...]

David A. Ahlquist1, Joel Skoletsky, Kevin A. Boynton, Jonathan J. Harrington1, Douglas W. Mahoney1, William Pierceall, Stephen N. Thibodeau1, Anthony P. Shuber •
Mayo Clinic1
01 Nov 2000-Gastroenterology
TL;DR: Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia, and sensitivities for cancer were unchanged but decreased slightly for adenomas, while specificity increased to 100%.
Journal Article•10.1016/S0016-5085(00)70354-4•
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

[...]

Jean-Frederic Colombel, Nicolas Ferrari, Hervé Debuysere, Philippe Marteau, Jean Pierre Gendre, Bruno Bonaz, Soulé Jc, Robert Modigliani, Yvan Touze, Pascale Catala, Christian Libersa, Franck Broly 
01 Jun 2000-Gastroenterology
TL;DR: Twenty-seven percent of patients with CD and myelosuppression during azathioprine therapy had mutant alleles of the TPMT gene associated with enzyme deficiency, which is more often caused by other factors than other factors.
Journal Article•10.1016/S0016-5085(00)70412-4•
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.

[...]

Timothy C. Wang1, Charles A. Dangler2, Duan Chen3, James R. Goldenring4, Theodore J. Koh1, Raktima Raychowdhury1, Robert J. Coffey5, Sus Ito1, Andrea Varro6, Graham J. Dockray6, James G. Fox2 •
Harvard University1, Massachusetts Institute of Technology2, Lund University3, Georgia Regents University4, Vanderbilt University Medical Center5, University of Liverpool6
01 Jan 2000-Gastroenterology
TL;DR: Findings support the unexpected conclusion that chronic hypergastrinemia in mice can synergize with Helicobacter infection and contribute to eventual parietal cell loss and progression to gastric cancer.
Journal Article•10.1016/S0016-5085(00)70183-1•
AGA technical review on intestinal ischemia

[...]

Lawrence J. Brandt1, Scott J. Boley1•
Albert Einstein College of Medicine1
01 May 2000-Gastroenterology
Journal Article•10.1016/S0016-5085(00)70224-1•
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.

[...]

Bruno Stieger1, Karin Fattinger1, Jerzy Madon1, Gerd A. Kullak-Ublick1, Peter J. Meier1 •
University of Zurich1
01 Feb 2000-Gastroenterology
TL;DR: Bsep is identified as an important target for induction of drug- and estrogen-induced cholestasis in mammalian liver through ATP-dependent taurocholate transport in cLPM vesicles.
Journal Article•10.1053/GAST.2000.8521•
Current concepts of celiac disease pathogenesis

[...]

Detlef Schuppan1•
University of Erlangen-Nuremberg1
01 Jul 2000-Gastroenterology
TL;DR: In this paper, Tissue transglutaminase, which has been identified as the highly specific endomysial autoantigen, is released from cells during inflammation, and it may potentiate antigen presentation by HLA-DQ2 and DQ8 by deamidating or cross-linking gluten peptides.
Journal Article•10.1016/S0016-5085(00)70192-2•
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

[...]

Willis C. Maddrey1•
University of Texas Southwestern Medical Center1
01 May 2000-Gastroenterology
Journal Article•10.1016/S0016-5085(00)70430-6•
AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding.

[...]

Gary R. Zuckerman1, Chandra Prakash1, Matthew P. Askin2, Basil S. Lewis2•
Washington University in St. Louis1, Mount Sinai Hospital2
01 Jan 2000-Gastroenterology
TL;DR: This literature review and the recommendations therein were prepared for the American Gastroenterological Association Clinical Practice and Practice Economics committee and were approved by the committee on May 16, 1999 and by the AGA governing board on July 18, 1999.
Journal Article•10.1053/GAST.2000.18017•
SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis.

[...]

Roland H. Pfützer, M. Michael Barmada, Andrew Brunskill, Robert Finch, P. Suzanne Hart1, John P. Neoptolemos2, William Furey, David C. Whitcomb •
University of Pittsburgh1, University of Liverpool2
01 Sep 2000-Gastroenterology
TL;DR: Modeling and familial clustering suggest that SPINK1 mutations are disease modifying, possibly by lowering the threshold for pancreatitis from other genetic or environmental factors, but by themselves do not cause disease.
Journal Article•10.1053/GAST.2000.20229•
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

[...]

Richard N. Fedorak1, Alfred Gangl2, Charles O. Elson3, Paul Rutgeerts4, Stefan Schreiber5, Gary Wild6, Stephen B. Hanauer7, Ann Kilian8, Marielle Cohard8, Alexandre LeBeaut8, Brian G. Feagan9 •
University of Alberta1, Medical University of Vienna2, University of Alabama at Birmingham3, Katholieke Universiteit Leuven4, Charité5, McGill University6, University of Chicago7, Schering-Plough8, University of Western Ontario9
01 Dec 2000-Gastroenterology
TL;DR: Subcutaneous rhuIL-10 administered daily for 28 days to patients with mild to moderately active Crohn's disease is safe, well-tolerated, and shows clinical and endoscopic improvement.
Journal Article•10.1053/GAST.2000.20227•
Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans

[...]

Pascal Crenn, Colette Coudray–Lucas, François Thuillier, Luc Cynober, Bernard Messing 
01 Dec 2000-Gastroenterology
TL;DR: In patients with short-bowel syndrome, postabsorptive plasma citrulline concentration is a marker of functional absorptive bowel length and, past the 2-year adaptive period, a powerful independent indicator allowing distinction of transient from permanent intestinal failure.
Journal Article•10.1053/GAST.2000.9561•
Nonsteroidal anti-inflammatory drug gastropathy

[...]

Christopher J. Hawkey1•
Queen's University1
01 Aug 2000-Gastroenterology
TL;DR: Risk is dose dependent and is lower with ibuprofen at low doses than with other NSAIDs, and it is unlikely that Helicobacter pylori increases the risk, and under some circumstances it may be protective.
Journal Article•10.1016/S0016-5085(00)70368-4•
Angiotensin II induces contraction and proliferation of human hepatic stellate cells

[...]

Ramon Bataller, Pere Ginès, Josep M. Nicolás, M. Nieves Görbig, Eva Garcia–Ramallo, Xavier Gasull1, Jaime Bosch, Vicente Arroyo, Juan Rodés •
University of Barcelona1
01 Jun 2000-Gastroenterology
TL;DR: The results suggest that activated HSCs are targets of the vasoconstrictor action of ANGII in the intrahepatic circulation, and ANGII induces contraction and is mitogenic for human-activated H SCs by acting through AT1 receptors.
Journal Article•10.1053/GAST.2000.16508•
Colon cancer screening

[...]

Randall W. Burt1•
University of Utah1
01 Sep 2000-Gastroenterology
Journal Article•10.1053/GAST.2000.20844•
A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions.

[...]

Mark Appleyard1, Zvi Fireman, Arkady Glukhovsky, Harold Jacob, Reuven Shreiver, S S Kadirkamanathan, Alexandra Lavy, Schlomo Lewkowicz, Eytan Scapa, Rona Shofti, Paul Swain, Assaf Zaretsky •
Royal London Hospital1
01 Dec 2000-Gastroenterology
TL;DR: Wireless capsule endoscopy detected more abnormalities in the small bowel than push enteroscopy in detecting small-bowel lesions.
Journal Article•10.1053/GAST.2000.20196•
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease

[...]

Stefan Schreiber1, Richard N. Fedorak2, Ole Haagen Nielsen3, Gary Wild4, C. Noel Williams5, Susanna Nikolaus1, Meron R. Jacyna, Bret A. Lashner6, Alfred Gangl, Paul Rutgeerts, Kim L. Isaacs7, Sander J. H. van Deventer8, J. C. Koningsberger9, Marielle Cohard10, Alesandre LeBeaut10, Stephen B. Hanauer11 •
University of Kiel1, University of Alberta2, Copenhagen University Hospital3, McGill University4, Dalhousie University5, Cleveland Clinic6, University of North Carolina at Chapel Hill7, University of Amsterdam8, Utrecht University9, Schering-Plough10, University of Chicago11
01 Dec 2000-Gastroenterology
TL;DR: Subcutaneous treatment with rhuIL-10 over 28 days induced a fully reversible, dose-dependent decrease in hemoglobin and thrombocyte counts but no clinically significant side effects and up to 8 μg/kg of rhu IL-10 was well tolerated.
Journal Article•10.1016/S0016-5085(00)70251-4•
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

[...]

Charlene M. Prather1, Michael Camilleri1, Alan R. Zinsmeister1, Sanna McKinzie1, George M. Thomforde1 •
Mayo Clinic1
01 Mar 2000-Gastroenterology
TL;DR: Tegaserod accelerates orocecal transit, tends to accelerate colonic transit, and deserves further study in patients with constipation-predominant IBS.
...

Tools

SciSpace AgentBiomedical AgentSciSpace RecruitSciSpace for EnterpriseAgent GalleryChat with PDFLiterature ReviewAI WriterFind TopicsParaphraserCitation GeneratorExtract DataAI DetectorCitation Booster

Learn

ResourcesLive Workshops

SciSpace

CareersSupportBrowse PapersPricingSciSpace Affiliate ProgramCancellation & Refund PolicyTermsPrivacyData Sources

Directories

PapersTopicsJournalsAuthorsConferencesInstitutionsCitation StylesWriting templates

Extension & Apps

SciSpace Chrome ExtensionSciSpace Mobile App

Contact

support@scispace.com
SciSpace

© 2026 | PubGenius Inc. | Suite # 217 691 S Milpitas Blvd Milpitas CA 95035, USA

soc2
Secured by Delve